I-SPY 2 trial shows promising development for some breast cancer patients using neratinib

Genetic testing can improve selection of women with ER positive breast cancer for ten rather than five years of hormonal therapy

EBCC 2014 key messages to doctors

Ganetespib in first-line treatment of women with metastatic HER2 positive or triple negative breast cancer

The 1st Immunotherapy of Cancer Conference (ITOC)

Novel CEA-targeted IL2 variant immunocytokine for immunotherapy of cancer

Sharing Indian perspectives on CRPC

The future of mCRPC treatment - expert discussion

Insights into mCRPC in China, Thailand and Indonesia - expert discussion

Cost constraints affect treatment decision-making in China and Singapore - expert discussion

mCRPC management in Taiwan - expert interview

Mechanisms of action and robotics in mCRPC